Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just listen to the CC. Nader bumbles his words when talking about the EUA. He often will put contradictory statements in the same sentence when he wants you to believe something that isn't true. He has not applied for an EUA. He contacted the FDA about applying. Big difference.
Does anyone wonder if quid pro quo was going on with the hire of Dr Recknor? Our trials had stalled with enrollment. He single-handedly kept the trial enrolling. And then they give him a ton of money for a job he is unqualified. Doesn't pass the smell test.
So does anyone have a link that shows that leronlimab in under review by the FDA or are those posts a complete fabrication? Not cool posting information from the Health Canada site and claiming it came from the FDA site.
I wonder if last Friday's short attack was a complete failure and Shorts got stuck in a short position they didn't want. 2.9 million shares were sold and the stock price dropped less than $2. I'm sure they anticipated the stock price dropping further. They immediately bought back sending the stock price shooting up to $15.40. Far more shares were sold than rebought. So they might have still been short at the end of trading Friday. At some point, they'll need to buy shares to cover their position. Hopefully, some of them are now researching lenzilumab and realizing that they don't want to be short this stock when data comes out. GM-CSF baby!
So last Friday's drop was a short attack. Makes sense since they bought back right away. The stock price really didn't drop much considering how many shares were sold. They probably didn't make much or any money on it.
Knowing that Nomis is still at 9.99% ownership makes me feel better. Shorts have no idea if data will be good. Shorts have never even heard of GM-CSF.
Below is a recent quote from Janet Woodcock where she basically says testing monoclonal antibodies on Mild-to-Moderate was a complete waste of time. She actually uses the word "dumb".
And then she says that they didn't realize it at first but a study of 400 is way too small. It is almost like they was specifically talking about both leronlimab trials.
Did CytoDyn management directly give us the critical numbers of 47% mortality in the placebo arm and 38% mortality in the treatment arm or were those numbers deduced from when Nader said the absolute reduction was 9% and the relative reduction was 24%?
38% mortality in the leronlimab arm of the critical patients is not good no matter if the placebo arm had 47% mortality. I realize these patients were critical but still. 62% survival just isn't a good result.
Uh oh, down to $13.02. Scooter, let the hate flow through you. We need you buddy.
I think I have to take CYDY off of my Google Alerts because I'm getting flooded with lawsuit notices. Do you think I can become a plaintiff despite making a bunch of money on CYDY? I sold at $6.50 but I could have sold at $10.01. But I wasn't fooled by Nader. He isn't the reason I held on past ten dollars. That honor would go to Bruce "it's rantes" Patterson. Guess what Bruce, it's not Rantes, it's GM-CSF.
HGEN is up to $13.60 in afterhours. Thanks for the boost, Scooter.